| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 473* | 2021 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 317 | 2021 |
| An update on the pathogenesis and treatment of IgA nephropathy JK Boyd, CK Cheung, K Molyneux, J Feehally, J Barratt Kidney international 81 (9), 833-843, 2012 | 226 | 2012 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 219 | 2022 |
| New insights into the pathogenesis of IgA nephropathy SC Yeo, CK Cheung, J Barratt Pediatric Nephrology 33, 763-777, 2018 | 156 | 2018 |
| Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis RM Smith, RB Jones, U Specks, S Bond, M Nodale, R Aljayyousi, ... Annals of the rheumatic diseases 79 (9), 1243-1249, 2020 | 139 | 2020 |
| Electronic consultation as an alternative to hospital referral for patients with chronic kidney disease: a novel application for networked electronic health records to improve … J Stoves, J Connolly, CK Cheung, A Grange, P Rhodes, D O'Donoghue, ... Quality and Safety in Health Care 19 (5), e54-e54, 2010 | 117 | 2010 |
| Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the … J Barratt, R Lafayette, J Kristensen, A Stone, D Cattran, J Floege, V Tesar, ... Kidney international 103 (2), 391-402, 2023 | 110 | 2023 |
| By what mechanism do leeches help to salvage ischaemic tissues?: A review IS Whitaker, CK Cheung, CAA Chahal, ROS Karoo, A Gulati, ITH Foo British Journal of Oral and Maxillofacial Surgery 43 (2), 155-160, 2005 | 93 | 2005 |
| New strategies and perspectives on managing IgA nephropathy H Selvaskandan, CK Cheung, M Muto, J Barratt Clinical and experimental nephrology 23, 577-588, 2019 | 86 | 2019 |
| Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial HJL Heerspink, J Radhakrishnan, CE Alpers, J Barratt, S Bieler, U Diva, ... The Lancet 401 (10388), 1584-1594, 2023 | 78 | 2023 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 76 | 2022 |
| Statins and cardiovascular primary prevention in CKD: a meta-analysis RW Major, CK Cheung, LJ Gray, NJ Brunskill Clinical Journal of the American Society of Nephrology 10 (5), 732-739, 2015 | 67 | 2015 |
| An update on the current state of management and clinical trials for IgA nephropathy CK Cheung, A Rajasekaran, J Barratt, DV Rizk Journal of clinical medicine 10 (11), 2493, 2021 | 54 | 2021 |
| Rituximab in adult minimal change disease and focal segmental glomerulosclerosis-What is known and what is still unknown? P Gauckler, JI Shin, F Alberici, V Audard, A Bruchfeld, M Busch, ... Autoimmunity reviews 19 (11), 102671, 2020 | 53 | 2020 |
| Rituximab in membranous nephropathy P Gauckler, JI Shin, F Alberici, V Audard, A Bruchfeld, M Busch, ... Kidney International Reports 6 (4), 881-893, 2021 | 52 | 2021 |
| Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney K Basnayake, CK Cheung, M Sheaff, W Fuggle, D Kamel, S Nakoinz, ... Journal of clinical pathology 63 (10), 884-887, 2010 | 50 | 2010 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10320), 143-151, 2022 | 45 | 2022 |
| Monitoring immune responses in IgA nephropathy: biomarkers to guide management H Selvaskandan, S Shi, S Twaij, CK Cheung, J Barratt Frontiers in Immunology 11, 572754, 2020 | 42 | 2020 |
| Risk factors for severe outcomes in patients with systemic vasculitis and COVID‐19: a binational, registry‐based cohort study MA Rutherford, J Scott, M Karabayas, M Antonelou, S Gopaluni, D Gray, ... Arthritis & Rheumatology 73 (9), 1713-1719, 2021 | 40 | 2021 |
